BioXcel Therapeutics, Inc. - Special Call Transcript
Hello and welcome to the BioXcel Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
I will now turn the call over to BioXcel's CEO, Vimal Mehta. Thank you, sir. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining our conference call today to discuss our positive top line results from the Phase Ib/II TRANQUILITY trial for the acute treatment of agitation in dementia, including Alzheimer's disease.
This is an exciting day for BioXcel Therapeutics and a hopeful day for dementia patients and their caregivers. As you can imagine from the press release we issued this morning, we are delighted by the findings of the TRANQUILITY study showing that BXCL501 was well tolerated, and demonstrated rapid and durable reductions in agitation in patients with dementia. A copy of the press release is available on BioXcel Therapeutics website. As a reminder, we will be making forward-looking
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |